Dabigatran etexilate and reduction in serum apolipoprotein B -

Dabigatran etexilate and reduction in serum apolipoprotein B
Information type: Other primary research
Source: Heart
Specialities: Cardiovascular system disorders | Haematological disorders
Summary
This data review of 2513 patients in the RE-LY trial showed that dabigatran therapy reduced apolipoprotein B after 3 months treatment by -0.057 g/L and -0.065g/L at low dose (110mg bd) and high dose (150mg bd) respectively whereas no reduction was seen with warfarin.
UKMi comment
A related editorial discusses this subanalysis detailing that the apparent additional pharmacological action warrants further investigation as it has the potential attenuate an extra cardiovascular risk factor
Related links: Related editorial